posted
Up at .85 as we write. Small o/s of 32.5 million . Nearly a million traded this morning =record volume.
MultiCell Immunotherapeutics Data Demonstrates Potential to Prevent Avian Flu; Pre-Clinical Mouse Models Show 1,000-fold Reduction in Viral Load in H1N1 Strain
2005-10-21 09:00 ET - News Release
LINCOLN, R.I. -- (Business Wire) -- Oct. 21, 2005
MultiCell Technologies, Inc. (OTCBB: MCET) announced today that pre-clinical tests conducted by scientists at MultiCell's San Diego laboratories showed that MultiCell Immunotherapeutics, Inc.'s (MCTI's) toll receptor technology was able to reduce pulmonary virus titers by 1,000- fold in the H1N1 strain of flu to barely detectable levels. These results indicate that the technology may be able to reduce viral load in avian influenza. The H5N1 avian flu contains many of the same proteins as the H1N1 strain of flu, so the HINI results are projected to be important to the understanding of developing an immunotherapeutic against avian flu. MCTI's toll receptor technology employs double stranded RNA (dsRNA) and targets toll receptors 3,7 and 8. In studies of mouse models, the viral load was reduced by more than 90%. The results of the study showed that more than 100,000 units of pulmonary viral titers were reduced to negligible levels after administration of the immunotherapeutic. The Company plans additional pre-clinical trials to further evaluate the methodology and plans to approach the Centers for Disease Control and Prevention to conduct further studies. MultiCell acquired the technology as a result of its acquisition last month of substantially all of the assets of Astral, Inc. "The pre-clinical results in mouse models support our view that our toll receptor technology may be able to respond to threats posed by agents such as avian influenza. We believe that these results highlight the commercial opportunities for our immunotherapeutics," said Dr. Stephen Chang, President of MultiCell Technologies Inc. "The recent acquisition of the assets of Astral has broadened our intellectual property platform considerably, and provides us with additional promising therapeutic opportunities."
About Avian Flu
Avian influenza attacks and destroys the human respiratory system and "... kills 55% of the people it infects," according to Laurie Garrett, senior fellow for global health at the Council on Foreign Relations. Avian flu can be contracted by bird, animal or human contact or airborne. It can spread at a rate three times faster than normal flu. For the newer strain of the disease, H5N1, there are no antibodies; this virus could pose a greater threat than smallpox, AIDS or anthrax.
About MultiCell Technologies, Inc.
MultiCell Technologies is a developer of therapies, an adult stem cell company and a supplier of immortalized cell lines for drug discovery applications. With its subsidiary, MultiCell Immunotherapeutics (MCTI), MultiCell intends to commercialize new therapeutics for the treatment of various diseases and disorders. MultiCell holds key patents relating to novel strategies for the isolation of adult human liver cells, and cell clusters or doublets as well as additional patents in the areas of stem cell technology, the Sybiol(TM) synthetic bio-liver therapeutic liver assist device, and immortalized human hepatocytes. MultiCell's stem cells are derived from adult tissues, which avoids the ethical and contamination issues associated with embryonic stem cells. MultiCell's headquarters and research laboratories are at 701 George Washington Highway, Lincoln, Rhode Island 02865. For more information about MultiCell see http://www.multicelltech.com.
-------------------- The Mouse Posts: 443 | From: Valemount | Registered: Dec 2003
| IP: Logged |
posted
Watch for a follow-through on Monday - if volume remains high monday morning this one wil likely get another 50% pop - and this will still not take it halfway to yearhigh of 2.40. MCET finished friday * .82
-------------------- The Mouse Posts: 443 | From: Valemount | Registered: Dec 2003
| IP: Logged |
posted
Volume slowed a bit today and so the price declined, but I would keep an eye on it as there may still be a follow through after some profittaking today. Selling really slowed at the end of the day as not many willing to part with their shares * .72 or lower.
-------------------- The Mouse Posts: 443 | From: Valemount | Registered: Dec 2003
| IP: Logged |
posted
Finished the week at .90 but volume slowed considerably. But apparently not many sellers at these prices as it continues to creep up towards a buck.
-------------------- The Mouse Posts: 443 | From: Valemount | Registered: Dec 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
